Clinical Trials Browser

Phase 2 × Inflammatory Breast Neoplasms × atezolizumab × Clear all

NCT03202316 2025-12-16

Atezolizumab, Cobimetinib, and Eribulin in Treating Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer

Phase 2 Active not recruiting

Inflammatory Breast Neoplasms